Cargando…

Normalization of CSF pTau measurement by Aβ(40) improves its performance as a biomarker of Alzheimer’s disease

BACKGROUND: Alzheimer’s disease (AD)-related tauopathy can be measured with CSF phosphorylated tau (pTau) and tau PET. We aim to investigate the associations between these measurements and their relative ability to predict subsequent disease progression. METHODS: In 219 cognitively unimpaired and 12...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Tengfei, Korman, Deniz, La Joie, Renaud, Shaw, Leslie M., Trojanowski, John Q., Jagust, William J., Landau, Susan M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7429887/ https://www.ncbi.nlm.nih.gov/pubmed/32799929 http://dx.doi.org/10.1186/s13195-020-00665-8

Ejemplares similares

Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
por: Meredith Jr., Jere E., et al.
Publicado: (2013)

Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
por: Blennow, Kaj, et al.
Publicado: (2019)

Cortical microstructural associations with CSF amyloid and pTau
por: Nir, Talia M., et al.
Publicado: (2023)

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2014)

Plasma pTau181 as a biomarker for Alzheimer's disease
por: Meng, Jie, et al.
Publicado: (2020)

Evaluation of a visual interpretation method for tau‐PET with (18)F‐flortaucipir
por: Sonni, Ida, et al.
Publicado: (2020)

Accumulation of pTau231 at the Postsynaptic Density in Early Alzheimer’s Disease
por: Lilek, Jaclyn, et al.
Publicado: (2023)

Comparing tau status determined via plasma pTau181, pTau231 and [(18)F]MK6240 tau-PET
por: Tissot, Cécile, et al.
Publicado: (2022)

Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer’s disease
por: Tissot, Cécile, et al.
Publicado: (2021)

A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer’s Disease Continuum
por: Coomans, Emma M., et al.
Publicado: (2023)

Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2023)

Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease
por: Fagan, Anne M, et al.
Publicado: (2009)

High altitude is associated with pTau deposition, neuroinflammation, and myelin loss
por: Iacono, Diego, et al.
Publicado: (2022)

ApoER2-Dab1 disruption as the origin of pTau-related neurodegeneration in sporadic Alzheimer’s disease
por: Ramsden, Christopher E., et al.
Publicado: (2023)

ApoER2-Dab1 disruption as the origin of pTau-related neurodegeneration in sporadic Alzheimer’s disease
por: Ramsden, Christopher E, et al.
Publicado: (2023)

Age, vascular disease, and Alzheimer’s disease pathologies in amyloid negative elderly adults
por: Guo, Tengfei, et al.
Publicado: (2021)

A Longitudinal Study of Plasma pTau181 in Mild Cognitive Impairment with Lewy Bodies and Alzheimer's Disease
por: Thomas, Alan J., et al.
Publicado: (2022)

Potential association between frailty and pTau in community-dwelling older adults
por: Zhou, Lixing, et al.
Publicado: (2022)

Elevated CSF GAP-43 is Alzheimer’s disease specific and associated with tau and amyloid pathology
por: Sandelius, Åsa, et al.
Publicado: (2018)

Reduction of pTau and APP levels in mammalian brain after low-dose radiation
por: Iacono, Diego, et al.
Publicado: (2021)

Modeling Alzheimer’s disease related phenotypes in the Ts65Dn mouse: impact of age on Aβ, Tau, pTau, NfL, and behavior
por: Overk, Cassia, et al.
Publicado: (2023)

Tau-focused therapy and tau transmission: Implications for Alzheimer’s Disease and related tauopathies
por: Trojanowski, John Q
Publicado: (2013)

Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology
por: Suárez-Calvet, Marc, et al.
Publicado: (2019)

Detection of Alzheimer’s disease (AD) specific tau pathology with conformation-selective anti-tau monoclonal antibody in co-morbid frontotemporal lobar degeneration-tau (FTLD-tau)
por: Gibbons, Garrett S., et al.
Publicado: (2019)

CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease?
por: Hu, William T, et al.
Publicado: (2015)

Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults
por: Pereira, Joana B., et al.
Publicado: (2020)

Plasma neuronal exosomal levels of Alzheimer's disease biomarkers in normal aging
por: Abner, Erin L., et al.
Publicado: (2016)

Plasma tau in Alzheimer disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Plasma tau complements CSF tau and P-tau in the diagnosis of Alzheimer's disease
por: Fossati, Silvia, et al.
Publicado: (2019)

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
por: Dong, Ruocheng, et al.
Publicado: (2021)

Amyloid-β levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy
por: Oberstein, Timo Jan, et al.
Publicado: (2022)

CSF p-Tau levels in the prediction of Alzheimer's disease
por: Kandimalla, Ramesh J. L., et al.
Publicado: (2013)

CSF P-tau 231 as Biomarker in Alzheimer's Disease
por: Mukherjee, Adreesh, et al.
Publicado: (2022)

CSF neurogranin or tau distinguish typical and atypical Alzheimer disease
por: Wellington, Henrietta, et al.
Publicado: (2018)

The Expression of Cellular Prion Protein, PrPC, Favors pTau Propagation and Blocks NMDAR Signaling in Primary Cortical Neurons
por: Rivas-Santisteban, Rafael, et al.
Publicado: (2023)

CSF sTREM2 in delirium—relation to Alzheimer’s disease CSF biomarkers Aβ42, t-tau and p-tau
por: Henjum, Kristi, et al.
Publicado: (2018)

Resistance and resilience to Alzheimer’s disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort
por: Latimer, Caitlin S., et al.
Publicado: (2019)

(18)F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
por: Brier, Matthew R., et al.
Publicado: (2016)

CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders
por: Mattsson, N, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_1n9b1lpv6romht71p54d09jlee